The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Antibiotics in the clinical pipeline in 2013
Open accessAbstract
The continued emergence of multi-drug-resistant bacteria is a major public health concern. The identification and development of new antibiotics, especially those with new modes of action, is imperative to help treat these infections. This review lists the 22 new antibiotics launched since 2000 and details the two first-in-class antibiotics, fidaxomicin (1) and bedaquiline (2), launched in 2011 and 2012, respectively. The development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of the 49 compounds and 6 β-lactamase/β-lactam combinations in active clinical development are discussed, as well as compounds that have been discontinued from clinical development since 2011. New antibacterial pharmacophore templates are also reviewed and analyzed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Lipid A Modification Systems in Gram-Negative Bacteria
Raetz, C. R. H., Reynolds, C. M., Trent, M. S., & Bishop, R. E. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.010307.145803 · Cited by 1,340
Thoughts and facts about antibiotics: Where we are now and where we are heading
Bérdy, J. (2012) · The Journal of Antibiotics · doi:10.1038/ja.2012.27 · Cited by 1,165
Wellington, E. M., Boxall, A. B., Cross, P., Feil, E. J., Gaze, W. H., Hawkey, P. M., Johnson-Rollings, A. S., Jones, D. L., Lee, N. M., Otten, W., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70317-1 · Cited by 1,122
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils
Turner, J., Cho, Y., Dinh, N.-N., Waring, A. J., & Lehrer, R. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2206 · Cited by 798
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Self-citationSimons, A., Alhanout, K., & Duval, R. E. (2020) · Microorganisms · doi:10.3390/microorganisms8050639 · Cited by 547
The antibiotic resistance crisis, with a focus on the United States
Martens, E., & Demain, A. L. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.30 · Cited by 445
The Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310843 · Cited by 426
Antimicrobial peptides under clinical investigation
Koo, H. B., & Seo, J. (2019) · Peptide Science · doi:10.1002/pep2.24122 · Cited by 376
Therapeutic strategies to combat antibiotic resistance
Brooks, B. D., & Brooks, A. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.027 · Cited by 367
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
Self-citationThe Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
Laxminarayan, R., Van Boeckel, T., Frost, I., Kariuki, S., Khan, E. A., Limmathurotsakul, D., Larsson, D. G. J., Levy-Hara, G., Mendelson, M., Outterson, K., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30003-7 · Cited by 324
Applying evolutionary biology to address global challenges
Carroll, S. P., Jørgensen, P. S., Kinnison, M. T., Bergstrom, C. T., Denison, R. F., Gluckman, P., Smith, T. B., Strauss, S. Y., & Tabashnik, B. E. (2014) · Science · doi:10.1126/science.1245993 · Cited by 314
Natural Products as a Source for Novel Antibiotics
Moloney, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.001 · Cited by 308
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Self-citationAntibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Edwards, I. A., Elliott, A. G., Kavanagh, A. M., Zuegg, J., Blaskovich, M. A. T., & Cooper, M. A. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00045 · Cited by 277
Self-citationAntibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Self-citationBrown, D. G., May-Dracka, T. L., Gagnon, M. M., & Tommasi, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501552x · Cited by 253
Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”: Miniperspective
Bisacchi, G. S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501881c · Cited by 252
Antibiotic effectiveness: Balancing conservation against innovation
Laxminarayan, R. (2014) · Science · doi:10.1126/science.1254163 · Cited by 170
(2014) · doi:10.1097/mcc.0000000000000124 · Cited by 89
Müller, C., Binder, U., Bracher, F., & Giera, M. (2017) · Nature Protocols · doi:10.1038/nprot.2017.005 · Cited by 83
Cocozaki, A. I., Altman, R. B., Huang, J., Buurman, E. T., Kazmirski, S. L., Doig, P., Prince, D. B., Blanchard, S. C., Cate, J. H. D., & Ferguson, A. D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605127113 · Cited by 56
Gramicidin D enhances the antibacterial activity of fluoride
Nelson, J. W., Zhou, Z., & Breaker, R. R. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.061 · Cited by 15
Metadata
- Authors
- Butler, M. S., Blaskovich, M. A., & Cooper, M. A.
- Venue
- The Journal of Antibiotics
- Published
- 2013-09-04
- Volume
- 66
- Issue
- 10
- Pages
- 571-591
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W2916084778
- Cited by
- 433
- References
- 156
- FWCI
- 28.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.